Category Archives: Industry: Healthcare

Healthcare is an ever evolving industry, and field. These Press Releases, will keep you up to date on the newest, greatest, best, solutions available.

GeBBS to Sponsor Nashville based Dancing for Safe Haven Fund Raising Event


Through GeBBS foundation and various client partnerships, we continue to serve those in need with better healthcare, housing, education, and cervical cancer detection.

GeBBS Healthcare Solutions, Inc., a leading provider of revenue cycle management (RCM) solutions for Healthcare Providers and Payers, announced that it will be a presenting sponsor for the 11th Annual Dancing For Safe Haven along with Community Health Systems and HCA Healthcare/TriStar Health. The charity event will be held on Saturday, March 28, at the Omni Nashville Hotel, TN. Dancing for Safe Haven is a fun-filled evening of competition, dining and dancing, with last year’s event raising over $400,000 for Safe Haven Family Shelter.

The funds raised last year allowed Safe Haven to reach the organizational milestone of serving more than 300 families. Safe Haven was also able to house 100 families in large part because of the success of last year’s Dancing for Safe Haven. For more information about Dancing for Safe Haven, click here.

“We are truly honored to have GeBBS Healthcare Solutions as a presenting sponsor for this year’s Dancing for Safe Haven,” said Safe Haven CEO, Joyce Lavery. “It is inspiring to see so many come together to support Safe Haven Family Shelter in such a meaningful way. The money raised at this event allows us to give more families a place to call home.”

“We are proud and honored to be part of such a great cause,” commented Nitin Thakor, President and CEO, GeBBS Healthcare Solutions. “Through GeBBS foundation and various client partnerships, we continue to serve those in need with better healthcare, housing, education, and cervical cancer detection.”

About Safe Haven Family Shelter

For 35 years, Safe Haven has served as the premier shelter-to-housing program in Middle Tennessee that accommodates families experiencing homelessness. Safe Haven leads our community’s efforts to house, support, empower and advocate for families, allowing them to stay together. Transformative services focused on housing and employment provide families with the resources to become self-sufficient and successful. For more information, visit http://www.safehaven.org.

About GeBBS

GeBBS Healthcare Solutions is a leading provider of Revenue Cycle Management (RCM) services and solutions in Health Information Management (HIM), Accounts Receivable (AR), and Risk Adjustment outsourcing. GeBBS’ innovative technology, combined with its over 8,500-strong global workforce, helps clients improve financial performance, compliance, and patient satisfaction. Headquartered in Los Angeles, CA, GeBBS has won numerous accolades for its medical coding outsourcing and medical billing outsourcing, including being ranked in Modern Healthcare’s Top 20 Largest RCM Firms, KLAS, Black Book Market Research’s Top 20 RCM Outsourcing Services, and Inc. 5000’s fastest growing private companies in the U.S. For more information, please visit http://www.gebbs.com.

For more information, press only: Contact Tyler Cowart, GeBBS Healthcare Solutions, Phone, 310-953-4444 ext. 214 Email: tyler.cowart@gebbs.com

Share article on social media or email:

Nationwide Vein Practice Commits to Increasing DVT Awareness


News Image

Raising awareness of this epidemic is important to the work of physicians across CVR. Chronic venous insufficiency, or vein disease, is more likely in patients that have had a DVT, and DVTs are one possible side effect of late stage vein disease.

For the sixth year in a row, Center for Vein Restoration (CVR) will be participating in national Deep Vein Thrombosis (DVT) Awareness Month. According to the American Heart Association, over 2.5 million Americans are affected by DVT annually, with over 600,000 people hospitalized each year. DVT, with its risk of pulmonary embolism, may be the most preventable cause of death among people hospitalized today in the United States. Despite its prevalence, many Americans are still unaware of the threat DVTs pose to their health.

Raising awareness of this epidemic is important to the work of physicians across CVR. Chronic venous insufficiency, or vein disease, is more likely in patients that have had a DVT, and DVTs are one possible side effect of late stage vein disease. The initial symptoms and risk factors for each condition are also similar. Early detection of DVTs is essential for successful treatment, and the vein disease screenings provided to each CVR patient can help identify DVTs.

Everyday, in its 84 practices across the nation, CVR provides DVT rule-out ultrasounds to patients referred by physicians who suspect a DVT but want to save their patients a costly, long, and stressful trip to the emergency room. CVR can also provide an immediate treatment plan for the DVT, or additional screening for vein disease, if needed.

CVR physicians educate about DVTs as a possible side effect of vein disease year-round. As part of CVR’s re-commitment to DVT Awareness Month in 2020, the company will be:

  • Distributing printed resources and magnets on DVT Symptoms and Risk Factors and a guide on DVT and Orthopedic Surgery to doctors’ offices nationwide
  • Focusing content on the urgency of DVTs in CVR blogs, commercials, interviews, and print ads
  • Rolling out a social media awareness campaign centered around the signs, symptoms and risk factors of DVTs and the connection to vein disease

Dr. Khanh Q. Nguyen, the Chief Medical Officer at CVR, is proud to lead CVR’s DVT Program. “Since 2014, we’ve managed over 3,000 DVT patients in the outpatient setting safely,” says Dr. Nguyen. “We are committed to providing state of the art venous care and complete DVT management while maintaining close communication with the referring physician.”

DVT Awareness Month was established in 2003 and sponsored by the Coalition to Prevent Deep-Vein Thrombosis. March is officially recognized as Deep-Vein Thrombosis (DVT) Awareness Month by United States Senate Resolution 56.

For more on CVR’s awareness campaign, follow:

ABOUT DEEP VEIN THROMBOSIS

A Deep Vein Thrombosis (DVT) is a dangerous blood clot that can form in the leg veins, or in other places in the body. The clot can be dislodged and move to other veins and arties, causing heart attack, stroke or plumonary embolism. Clots form when circulation is hindered by thick blood, genetic or hormonal factors, slow blood flow, inactivity or damaged veins. DVTs are most common in adults over age 60, but can occur at any age. Blood is more likely to clot, and vein valves are more likely to fail, for moms and pregnant women, smokers, long-distance travelers and those taking birth control pills, among other risk factors.

ABOUT VENOUS INSUFFICIENCY

Venous insufficiency, the cause of significant suffering due to the sequelae of venous hypertension, most commonly arises as achy, tired and heavy legs. It may or may not be associated with varicose veins, spider veins or skin changes including venous ulcerations and indiscriminately affects between 30–40 million Americans. Numerous factors including age, weight, prolonged sitting or standing, genetics or a history of DVT (blood clots) can increase the risk of developing this common and often underdiagnosed disorder. Treatment options have evolved to an array of minimally invasive procedures in an office setting.

ABOUT CENTER FOR VEIN RESTORATION

Center for Vein Restoration (CVR) is the largest physician-led practice treating vein disease in the country. Having performed its first procedure in 2007 under President and CEO Dr. Sanjiv Lakhanpal, Center for Vein Restoration has since become nationally recognized as the clinical leader in treating chronic venous insufficiency. With 84 centers and growing, CVR has over 500 employees and conducts over 200,000 patient interactions annually. To learn more about CVR and its mission, visit http://www.centerforvein.com or by phone at 1-800-FIX-LEGS.

Share article on social media or email:

New Cambro Decor Series Camtrays Look, Feel like Woodgrain


News Image

Décor Series Camtrays trays are ideal for operations ranging from high-traffic foodservice establishments to healthcare settings.

The newest Camtray by Cambro Manufacturing is a modern, durable and functional piece that will elevate the look of your operation. The Décor Series Camtrays are designed to appear and feel like authentic wood while actually being made of a durable fiberglass material. These Camtrays convey a modern-rustic vibe while providing the long-lasting durability of the classic Camtray.

Décor Series Camtrays can be made with a standard woodgrain textured surface or with Cambro’s clear non-skid surface called EpicTread™. EpicTread provides safer handling, a reduction in accidental spills and the elimination of tray mats. Decrease on-going costs while reducing waste when choosing an EpicTread surface. Décor Series Camtrays trays are ideal for operations ranging from high-traffic foodservice establishments to healthcare settings.

Choose from three tray sizes and five colors of woodgrain; personalization is also available. Promote the branding of your business by personalizing the front, back or both with a full-color logo or design.

Décor Series Camtrays are scratch, chip, break, stain and chemical resistant, in addition to coming with a five-year prorated warranty. Both surface textures are safe for use in high temperature dishwashers.

About Cambro Manufacturing

Cambro Manufacturing is a leading manufacturer and distributor of equipment and products to the foodservice industry worldwide. Brothers William and Argyle Campbell founded Cambro in 1951 with a small factory in Huntington Beach, Calif. More than 60 years later, Cambro is still a family-owned and privately held company committed to innovation, quality and value. More information on Cambro is available at http://www.cambro.com.

Share article on social media or email:

Hera BioLabs (“Hera”) and Demeetra Ag Bio (“Demeetra”) announce joint launch of Cas-CLOVER™ the “clean alternative to CRISPR/Cas9 for drug discovery and bioprocessing”


Cas-CLOVER – the best of both CRISPR/Cas9 and TALEN gene editing

“High fidelity editing is extremely important to us and our partners as off-targets can effect important characteristics…

Announcement Key Points:

Hera and Demeetra stem from the gene editing platforms company Transposagen (now a Hera BioLabs company) which is best known for its commercialization of the piggyBac® transposase

Cas-CLOVER differs from single-guided CRISPR and dual-guided CRISPR nickase systems as it is truly dimeric and demonstrates high fidelity with no detectable off-targets while maintaining robust editing efficiency

Issued patents cover these technologies enabling clear freedom-to-operate

Evaluation opportunities and services for Cas-CLOVER which can convert into full research and commercial licenses with very accessible terms are available

Demeetra is operating in the pharmaceutical/industrial bioprocessing space as well as agricultural biotechnology, while Hera is focused on products tools and services for research and drug discovery

Targeted nuclease gene editing is a powerful tool for accelerating and improving opportunities for successful drug and cell therapy development from target identification and candidate selection through the production of GMP biologics. And has been used successfully to engineer T-cell therapies. Technologies such as ZFNs, CRISPR/Cas9 and now Cas-CLOVER bind to the target DNA and generate insertions and deletions (“indels”) resulting in “knockout” mutations or targeted “knock-ins” when supplied with the appropriate guide RNA(s) and donor vector.

CRISPR/Cas9 was a breakthrough for gene editing since it offers a simple and cost-effective method for high efficiency modification of the desired target locus. CRISPR does have a known trade-off as the technology demonstrates high degrees of off target mutagenesis, modifying the genome at undesired locations, in addition to the gene of interest. Off-target mutagenesis also occurs with the dual guided CRISPR nickase system which has been characterized as not truly dimeric (1, 2). Furthermore, licensing restrictions or lack of clear commercial freedom to operate have limited CRISPR/Cas9 use commercially.

Unlike CRISPR/Cas9, which is a monomeric nuclease targeted by a single guide RNA, Cas-CLOVER is a dimeric nuclease system targeted by 2 guide RNAs and has no detectable off-target mutations (3).

The Cas-CLOVER dimeric system uses two guide RNAs targeting “half-site” sequences. The two half-sites are separated by a spacer region where genomic DNA is cleaved with the proprietary dimeric Clo51 nuclease. The stringency of the dimeric Clo51 nuclease gives it the specificity that has shown no off-target activity after millions of next generation sequencing (NGS) reads in human T-cells. Guide RNA design for any gene of interest is flexible, as the spacer region between the guides is ideally between 16-30 bases (4).

“High fidelity editing is extremely important to us and our partners as off-targets can effect important characteristics such as growth rate and cloning efficiency in bioprocessing systems” said Jack Crawford CEO of Demeetra. Demeetra and Hera recently collaborated to validate Cas-CLOVER in Chinese hamster ovary (CHO) cell lines for bioprocessing. “Cas-CLOVER is a perfect fit for us as we move into crop trait engineering where we want to minimize off-target risks and reduce timelines due to backcrossing which is required with traditional chemical mutagenesis” he added.

Hera’s SRG OncoRat® is another example of nuclease applications. The Sprague Dawley strain was engineered to contain a knockout in both the Rag2 and IL2rg genes resulting in a fully immunodeficient rat. Dozens of human tumor models have been validated in the OncoRat, including a prostate cancer model recently published in a top tier drug development journal (5).

“Cell and gene therapy research may especially benefit from Cas-CLOVER where off-target mutagenesis is unacceptable” added Mike Schlosser the CEO of Hera. Both proliferating and resting human T-cells have been successfully targeted by Cas-CLOVER to remove cell surface markers associated with graft versus host disease (GVHD) (4).

About Hera

Hera Biolabs, Inc., based in Lexington, KY is an innovative preclinical contract services, products and licensing company. Our mission is to use cutting-edge gene-editing technologies to accelerate preclinical research and drug and cell-based therapeutic discovery and development. Hera built the SRG platform, an immunocompromised double knockout Sprague-Dawley rat engineered for T-cell, B-cell, and NK cell deficiency. Our first established commercial model is the SRG OncoRat, a valuable complement or alternative to oncology studies in mice, and well suited for xenograft oncology studies given its excellent tumor take-rates, large tumor mass, and smooth transition from efficacy to safety. Hera sells the SRG OncoRat to researchers and has been conducting oncology/pharmacology studies for clients over the past 5 years. Using immunocompromised husbandry procedures, our experienced staff performs studies in our on-site state-of-the-art vivarium that features dual HEPA-filtered, disposable IVC rodent caging systems. We’re also continuing to use our proprietary Cas-CLOVER CRISPR system and piggyBac gene-editing technologies and know-how to expand our robust pipeline of models and services.

About Demeetra

Demeetra AgBio is “Engineering Traits for Life” by introducing gene editing technologies in the agriculture, industrial, pharmaceutical & animal health industries. We provide licenses for Cas-CLOVER (the clean CRISPR/Cas9 alternative) and piggyBac transposase or partner under joint development agreements for applications in the engineering of crops and agricultural animals, plant-based drug development and enhanced bioprocessing in human & animal health.

References

1.    Tsai et al. (2014) Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nature Biotechnology.

2.    Lee et al (2015) Site-specific integration in CHO cells mediated by CRISPR/Cas9 and homology-directed DNA repair pathway. Scientific Reports

3.    Li et al (2018) Cas-CLOVER™: A High-Fidelity Genome Editing System for Safe and Efficient Modification of Cells for Immunotherapy. Precision CRISPR Congress Poster.

4.    Wang et al. (2017) Genome Editing of Therapeutic CAR-T Cells Using A Novel Clo51-dCas9 (NextGEN™) CRISPR System. American Society for Cell & Gene Therapy Poster.

5.    Ponnusamy (2019) Orally -Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. Clinical Cancer Research

Share article on social media or email:

New study identifies trigger that turns dormant cancer stem cells into active ones


News Image

A new study released today in STEM CELLS identifies, for the first time, two morphologically and functionally different types of cancer stem cells found in cervical cancer. Of the two types, one exhibits an overexpression of cPLA2α, a key enzyme that triggers the transformation of dormant cancer stem cells into active ones, resulting in cervical cancer metastasis and recurrence. The information in this study could lead to new targets for treatments to halt tumor recurrence and metastatic spread. Also, it might accelerate the development of combination therapies.

The current standard of treatments for cervical cancer – the second leading cause of cancer death in young women worldwide — is radiotherapy and chemotherapy. However, the cancer’s resistance to chemotherapy and radiation, combined with a tendency to metastasis in the lymph nodes or recur in the pelvis, leaves doctors searching for more effective treatments.

Cervical cancer stem cells (CCSCs) are considered the major culprit behind the cancer’s ability to overcome these treatments. At the same time, a majority of cancer stem-like cells or tumor-initiating cells remain dormant. It takes a change in their microenvironment to spur them to metastasize.

“The mechanisms responsible for this must be identified to design more suitable therapies for the different subpopulations of cancer stem cells (CSCs) in various tissue-specific cancers,” said Hua Guo, Ph.D., who headed up the investigation along with Yuchao He, Ph.D. The two are colleagues at Tianjin Medical University Cancer Institute and Hospital. Researchers at Tianjin University of Traditional Chinese Medicine and at the Center for Translational Cancer Research, Peking University First Hospital, also participated in the study.

Although several cell surface antigens have been identified in CCSCs, these markers vary among tumors because of CSC heterogeneity. However, whether these markers specifically distinguish CCSCs with different functions is unclear. The study published in STEM CELLS sought to resolve this question. And in fact, its findings demonstrate that CCSCs exist in two biologically distinct phenotypes, characterized by different levels of cPLA2α expression.

“Our study showed for the first time that overexpression of cPLA2α results in a phenotype associated with mesenchymal traits, including increased invasive and migration abilities. On the other hand, CCSCs with cPLA2α downregulation show dormant epithelial characteristics,” said Dr. Guo. “In addition, cPLA2α regulates the reversible transition between mesenchymal and epithelial CCSC states through PKCζ, an atypical protein that governs cancer cell state changes.”

Dr. He added, “Now that we know cPLA2α triggers this transformation, we believe that cPLA2α might be an attractive therapeutic target for eradicating different states of CCSCs to eliminate tumors more effectively.”

“The novel study by Dr. Guo and team is of very high importance in understanding the transition between dormant cancer stem cells, which evade chemotherapy and radiation treatments, and actively dividing cells which can be better targeted, said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. “I applaud the group for this important discovery which will help researchers develop better treatments for cervical cancer.”

###

The full article, “cPLA2α reversibly regulate different subsets of cancer stem cells transformation in cervical cancer,” can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/stem.3157.

Figure Caption: This study revealed that there are two morphologically and functionally distinct cancer stem cell populations regulated by cPLA2α in cervical cancer. cPLA2α might be a unique marker to identify different cancer stem cell populations and trigger quiescent epithelial cancer stem cells transform to invasive mesenchymal states. Overexpression of cPLA2α resulted in a CD44+CD24- phenotype with mesenchymal traits, whereas cervical cancer stem cells (CCSCs) with cPLA2α downregulation expressed CD133 and showed epithelial characteristics. cPLA2α, as a key role to reversely regulate CCSCs states and EMT, might provide innovative therapeutic strategies intended to halt tumor recurrence and metastasis.

About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS® (http://www.StemCells.com) is the world’s first journal devoted to this fast paced field of research. THE ONCOLOGIST® (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE® (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company’s website can be accessed at http://www.wiley.com.

Share article on social media or email:

Grain Foods Foundation Welcomes Siddhartha Angadi, PhD, FACSM, to Scientific Advisory Board


Siddhartha Angadi, PhD, FACSM

This is the perfect time to add Dr. Angadi’s expertise to the Foundation. We look forward to raising the visibility of the evidence-based dietary recommendations that result from his research among the nutrition community and the public.

The Grain Foods Foundation is excited to announce the addition of Siddhartha Angadi, PhD, FACSM, to its Scientific Advisory Board, effective February 1, 2020. A fellow of the American College of Sports Medicine, Dr. Angadi is currently an Assistant Professor at the College of Health Solutions at Arizona State University.

A cardiovascular exercise physiologist by training, Dr. Angadi’s research focuses on the complex interactions between exercise and physical activity, diet, and drugs in both healthy individuals and those with serious illnesses such as congestive heart failure, breast cancer, and end-stage renal disease.

“Given the rising prevalence of and deaths resulting from the illnesses that Dr. Angadi studies, this is the perfect time to add his expertise to the Foundation,” said Christine Cochran, executive director for the Grain Foods Foundation. “His research is impressive in both volume and breadth, and we look forward to raising the visibility of the evidence-based dietary recommendations that result from it among the nutrition community and the public.”

Dr. Angadi cites his most recent research – one Nutrients study that investigates the effects of glycemic index and dietary fiber on cardiovascular disease risk in adults, and another that examines the role of dietary fiber consumption on cardiovascular health in pediatric populations – as evidence that he clearly shares this ambition.

“I’m elated to join the Scientific Advisory Board,” Angadi said. “There’s a tremendous amount of misinformation out there when it comes to the role of diet in human health and disease, from one fad diet claiming that dietary fiber isn’t essential to another claiming that we’d all be better off without gluten. So I’m thrilled to partner with the Grain Foods Foundation and have the opportunity to help separate fact from fiction.”

Dr. Angadi joins the current members of the Scientific Advisory Board:

  • Glenn Gaesser, PhD (Chairman), Professor of Exercise Science and Health Promotion and Director of the Healthy Lifestyles Research Center at Arizona State University;
  • Dyan Hes, MD, owner and medical director of Gramercy Pediatrics in New York City;
  • Sylvia Melendez-Klinger, DBA, MS, RD, LDN, founder of Hispanic Food Communications;
  • Richard D. Mattes, MPH, PhD, RD, Distinguished Professor of Nutrition Science at Purdue University;
  • Julie Miller Jones, PhD, LN, CNS, Professor Emeritus at St. Catherine University;
  • Bruce Young, MD, Silverman Professor of Obstetrics and Gynecology at New York University School of Medicine;
  • Angela Ginn-Meadow, RD, LDN, CDE, Senior Education Coordinator at the University of Maryland’s Center for Diabetes and Endocrinology;
  • Pamela Cureton, RD, LDN, Division of Pediatric Gastroenterology and Nutrition at the University of Maryland School of Medicine;
  • Hannah Holscher, PhD, RD, Assistant Professor of Nutrition in the Department of Food Science and Human Nutrition at the University of Illinois.


About Grain Foods Foundation

Formed in 2004, Grain Foods Foundation (GFF) is a group of thought leaders and advocates for ALL grain foods and believes everybody needs grain food to enjoy a happy and healthy life. Committed to nutrition education programming that is firmly rooted in science, GFF is a strong advocate for our members, and a resource for consumers and the media who want to learn more about the role of grains in a well-balanced eating pattern. GFF offers research-based information and resources to members, partners, influencers, policymakers and consumers through a comprehensive communications campaign, conferences, webinars, research tools, social media and more. GFF is committed to bringing fact-based information and common sense to the consumer. For more information, visit grainfoodsfoundation.org.

Share article on social media or email:

Strategic Radiology Adds First Oregon Practice, Diagnostic Imaging Northwest


Diagnostic Imaging Northwest

Phillip Baker, MD, PhD, President, Diagnostic Imaging Northwest

Our philosophy of practice is to be an active and valued participant in our communities and the institutions where we provide care. We think that membership in Strategic Radiology and the SR–Patient Safety Organization will help us continue to put the patient and referring physician first.

Diagnostic Imaging Northwest (DINW) has aligned with Strategic Radiology’s coalition of independent private radiology practices, bringing the current number of members to 27 and bolstering the organization’s presence in the Northwest. The group includes 12 subspecialty-trained radiologists.

“We are pleased to be welcoming Diagnostic Imaging Northwest into the Strategic Radiology coalition of independent practices,” said Arl Van Moore Jr, MD, FACR, CEO and chair, Strategic Radiology. “The practice brings a combination of excellent, quality-minded radiologists, a demonstrated willingness to collaborate, and a commitment to Strategic Radiology’s core values.”

DINW was founded nearly 100 years ago and during the past century has built a strong relationship with Legacy Health’s Good Samaritan Hospital, a leading subspecialty hospital In Portland with an oncology center operated in partnership with Oregon Health & Science University. It also provides subspecialty coverage for Skyline Hospital, in White Salmon, Washington.

The practice’s radiologists serve as department medical directors at both hospital sites and provide diagnostic mammography and breast biopsy for a new breast center operated by Women’s Health Associates, a 100-physician group of primarily OB-GYN physicians.

“Our philosophy of practice is to be an active and valued participant in our communities and the institutions where we provide care,” said Phillip D. Baker, MD, PhD, president, DINW. “We think that membership in Strategic Radiology and the SR–Patient Safety Organization will help us continue to put the patient and referring physician first.”

DINW is a partner in Legacy Health Partners, an accountable care organization with more than 2,500 physician members. The practice has been an integral member of the Portland health care provider community since the 1920s, introducing Oregon’s first CT scanner and first dedicated breast imaging center, both at Legacy Good Samaritan.

About Strategic Radiology

Strategic Radiology is a coalition of independent, private radiology practices, representing more than 1,100 radiologists. The coalition’s goal is to achieve higher quality patient care and more cost-efficient delivery of medical imaging through an integrated approach of shared data and best practices, interchanging clinical expertise, and consolidating certain practice expenses. It operates the nation’s only radiology-focused Patient Safety Organization listed by the Agency for Healthcare Research and Quality. http://www.StrategicRadiology.org.

SR Members:


  • Asheville Radiology Associates; Asheville, NC
  • Casper Medical Imaging and Outpatient Radiology; Casper, WY
  • Central Illinois Radiological Associates; Peoria, IL
  • Diagnostic Imaging Northwest; Portland, OR
  • Gaston Radiology; Gastonia, NC
  • The Hill Medical Corporation; Pasadena, CA
  • Huron Valley Radiology; Ann Arbor, MI
  • Inland Imaging; Spokane, WA
  • Mecklenburg Radiology Associates; Charlotte, NC
  • Medical Center Radiology Group; Orlando, FL
  • Minneapolis Radiology Associates; Minneapolis, MN
  • Modesto Radiological Medical Group (MRMG); Modesto, CA
  • Mountain Medical Physician Specialists; Salt Lake City, UT
  • Naugatuck Valley Radiological Associates; Waterbury, CT
  • Northwest Radiology; Indianapolis, IN
  • Quantum Radiology; Atlanta, GA
  • Radiologic Medical Services; Iowa City, IA
  • Radiology Associates; Jeffersonville, IN
  • Radiology Associates of Macon; Macon, GA
  • Radiology Associates of North Texas; Dallas/Fort Worth, TX
  • Radiology Associates of Tallahassee; Tallahassee, FL
  • Rome Radiology Group; Rome, GA
  • Southeast Radiology, Ltd.; Glen Mills, PA
  • Tower Imaging Medical Group; Santa Monica, CA
  • United Imaging Consultants; Mission, KS
  • University Radiology; East Brunswick, NJ
  • X-Ray Consultants; South Bend, IN

Share article on social media or email:

EnduRx Pharmaceuticals Awarded $1.4MM of a $1.75MM Grant to Collaborate with MD Anderson Cancer Center to Develop a Novel Therapeutic for Triple-negative Breast Cancer


EnduRx Pharmaceuticals, advancing a drug delivery system intended to improve outcomes for patients with hard-to-treat solid tumors, has been awarded $1.4 million dollar Department of Defense grant. The 36-month project is a collaboration with MD Anderson Cancer Center in Houston and will advance a novel therapeutic for triple-negative breast cancer to the point of pre-IND meeting with the FDA. Total project grant award is $1.75 million dollars.

“With triple-negative breast cancer, so-called because it lacks the receptors that enable the use of treatments employed for other forms of breast cancer, only about 30% of patients at best respond to standard-of-care treatment.” said Stephan Morris, MD, EnduRx Principal Investigator. “There are currently few approved drugs available specifically for the treatment of this fast growing and poor-outcome type of breast cancer. Untreated, the cancer is likely to metastasize to the brain and parts of the body, and the five-year survival rate is then only a little over 10%, so there is an urgent need for an effective therapy,” Morris said. “This form of breast cancer is diagnosed in about 10-20% of breast cancer patients, with an even higher proportion occurring in African-American women. We are pleased to have this opportunity to work with Dr. Naoto Ueno’s breast cancer group at MD Anderson, whose access to patient-derived xenograft models should provide a high level of confidence that the EnduRx Pharmaceuticals therapeutic candidate will translate well into human subjects with triple-negative breast cancer.”

About EnduRx Pharmaceuticals

EnduRx Pharmaceuticals Inc., a Tucson firm, is part of OBDURO Biotechnologies, a San-Diego company formed in 2019, to improve delivery of drugs selectively to the site of disease and not elsewhere in the body. In 2020 OBDURO plans a funding round and will use the proceeds to further leverage the grant-sponsored activities and generate persuasive data aimed at securing pharma partnerships. EnduRx previously received a $1.75 million SBIR grant to develop a prototype of the drug delivery system. “Earlier work showed tumor-volume reductions of over 90% in mouse models, with some cures. The DoD grant will allow EnduRx to complete pharmacokinetic and toxicology analyses as well as additional anti-cancer efficacy studies, data which are required before clinical trials can be initiated.” said David Loynd, Chief Executive Officer of OBDURO and EnduRx.

About the Congressionally Directed Medical Research Programs:

CDMRP was established in 1992 when Congress first appropriated funds targeted specifically for breast cancer research. Since that time, additional research programs and topics have been added by Congress, and CDMRP has evolved into a global funding organization that fosters novel approaches to biomedical research in response to the expressed needs of its stakeholders — the American public, the military, and Congress. For more information about CDMRP go to https://cdmrp.army.mil/. The views expressed in this article are those of the author and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.

For further information:

David Loynd, President & CEO

EnduRx Pharmaceuticals, Inc.

dloynd@endurxpharm.com

(855) 368-2878

Share article on social media or email:

Memorial Neuroscience Institute Performs Its First Robotic Brain Surgery to Help Ease Epileptic Seizures


“We are committed in adopting technology that is at the forefront of surgical treatments for epilepsy. The use of the robot will help the Memorial Neuroscience Institute to provide the cutting edge care to our patients.”

The epilepsy team at Memorial Neuroscience Institute successfully completed its first use of a minimally-invasive, robotic device that helps pinpoint the origin of epileptic seizures on a patient.

The device, now in full use at Memorial Regional Hospital, is called a Robotized Surgical Assistant, or ROSA. With assistance from the robot, neurosurgeons only need to make small, precise incisions in the scalp and skull to place electrodes deep in the brain and investigate where seizures are triggered.

The robot also improves accuracy, safety and can significantly reduce total surgery time, said Tarek Zakaria, MD, Medical Director for the Adult Neurology Program and Epilepsy Program.

By using the new technology, more data will be available to the epilepsy team to offer patients more advanced treatment options and help them to achieve their dreams to be seizure free, Zakaria said.

“We are committed in adopting technology that is at the forefront of surgical treatments for epilepsy,” Zakaria said. “The use of the robot will help the Memorial Neuroscience Institute to provide the cutting edge care to our patients.”

When medication is not enough to control seizures, neurosurgeons like Christopher DeMassi, MD and Daxa Patel, MD may take a surgical approach. That includes altering or removing brain tissue at the location where a patient’s seizures begin. However, they can only do so if they can first zero in exactly where that origin is. This is where Rosa can assist.

Recently, they performed the two-part procedure on a 24-year-old female patient, who began having epileptic seizures at age eight and had exhausted all available medications.

The procedure, called robot-assisted stereoelectroencephalography (SEEG), was performed as part of the services offered by the Memorial Neuroscience Institute Comprehensive Epilepsy Center.

“Our goal is to always bring in the latest innovative technologies to achieve the best possible outcome for our patients,” DeMassi said. “This is just the latest advancement available to the South Florida community and keeps us at the front of epilepsy care.”

Surgeons used ROSA and a 3-D reconstruction of the patient’s brain to guide them where to surgically implant electrodes without having to remove sections of her skull. DeMassi and Patel then used the robot’s arm to make two- or three-millimeter holes in the scalp through which the electrode wires were passed.

With the electrodes in place, Zakaria and his team were later able to see part of the patient’s brain “light up” on a computer monitor as a seizure began, essentially flagging the point of origin.

“Memorial Neuroscience Institute is proud to offer the most technologically advanced and comprehensive services for our patients and the community,” said Haroula Protopapadakis Nordem, FACHE, Associate Administrator at Memorial Regional Hospital.

“The addition of the ROSA to our program will allow our surgeons to deliver more precise results in a less invasive manner and allow our physicians to treat patients who otherwise might not have had a feasible treatment option,” she said.

Memorial’s epilepsy center is accredited by the National Association of Epilepsy Centers (NAEC) as a Level 4 program, a designation for programs offering the highest level of comprehensive and specialized care.

Memorial Regional Hospital in Hollywood, Fla., is one of the largest hospitals in Florida and is a facility of Memorial Healthcare System, one of the largest healthcare systems in Florida. Its wide scope of medical services and programs includes Memorial Cancer Institute, Breast Cancer Center, Cardiac and Vascular Institute, Neuroscience Center, Comprehensive Weight-Loss Surgery Program, Family Birthplace, Center for Behavioral Health, Sickle Cell Day Hospital, Women’s Services, Fitness and Rehabilitation Center, and a level I Trauma Center. For more information, visit memorialregional.com.

Share article on social media or email:

Taxpayers Have Invested Billions In Electronic Health Records Systems


Doctors spend too much time away from patients because of burdensome technology and regulatory requirements.

New rules from the Department of Health & Human Services to give doctors more time with their patients may not perform as intended

In our view, improved patient access and experiences are relevant at the beginning of a patient’s care journey, when the decision whether or not to seek care is made. For patients, affordability has become a healthcare crisis. – Kevin Fleming, CEO, Loyale Healthcare

Just last week, the U.S. Department of Health and Human Services (HHS) released the final version of a comprehensive strategy developed jointly by the Centers for Medicare & Medicaid Services and the Office for the National Coordinator for Health Information Technology (ONC), following public comment solicited in late 2018. The document, “The Strategy on Reducing Regulatory and Administrative Burdens Relating to the Use of Health IT and EHRs (Electronic Healthcare systems)”, aims to apply the agencies’ rulemaking powers and considerable healthcare industry influence to “give clinicians more time to focus on what matters – caring for their patients.”

It is fair to say that everyone in the U.S. has an interest in the healthcare industry’s success improving the performance of their EHR systems – both as providers and patients. In research published nearly a year ago by Kaiser Health News and Fortune titled, “Death By 1,000 Clicks: Where Electronic Health Records Went Wrong.” The authors observed that “10 years after President Barak Obama signed a law to accelerate the digitization of medical records – with the federal government, so far, sinking $35 billion into the effort – American has little to show for its investment.”

The Fortune/KHN research goes on to state that “Rather than an electronic ecosystem of information, the nation’s thousands of EHRs largely remain a sprawling, disconnected patchwork. Moreover, the effort has handcuffed health providers to technology they mostly can‘t stand and has enriched and empowered the $13 -billion-a-year industry that sells it.”

Author, physician and CEO of Haven Healthcare Atul Gawande, also spoke to this issue in a New Yorker magazine article titled “Why Doctors Hate Their Computers” In it, Dr. Gawande asks “are screens coming between doctors and patients?” describing in detail the many negative outcomes for physicians and patients when doctors are required to interact with systems that were not designed to suit them or their work.

In an announcement from the Centers for Medicare and Medicaid Services (CMS) of the HHS strategy’s release, CMS administrator Seema Verna, noted that “The taxpayers made a massive investment in EHRs with the expectation that it would solve the many issues that plagued paper-bound health records. Unfortunately – as this report shows – the cure has been worse than the disease.” Ms. Verna went on to say that “it is unacceptable that the application of health IT still struggles to provider ready access to medical records, access that might mean the difference between life and death.”

HHS’s strategy report focuses on three primary goals, offering recommendations to:


  • Reduce the effort and time required to record information in EHRs for healthcare provider when they are seeing patients.
  • Reduce the effort and time required to meet regulatory reporting requirements of clinicians, hospitals and healthcare organizations; and
  • Improve the functionality and intuitiveness (ease of use) of EHRs


HHS’s strategy announcement has been met with a blend of optimism and skepticism. Healthcare providers and their agencies have complimented the agency’s attention to reducing excessive burden, a problem that is universally acknowledged among hospitals and other providers. However, in a comment published the day following the announcement, the American Hospital Association (AHA) stated that “some ONC recommendations…could have unintended consequences for adoption of current standards and would not address the lack of transparency or uniformity around payer requirements.”

The AHA went on to recommend that the agency “align Medicare and Medicaid clinician requirements in the Promoting Interoperability Program; improve its systems for attesting to meaningful use of EHRs (a condition for the above referenced federal funding); and improve its certification requirements.” The AHA also noted that “the lack of interoperability affects the usability of EHRs and urged the agencies to more forward with policies to support information exchange.”

As with any high-level strategy, the success of HHS’s proposal and the American healthcare industry’s effort to reduce the administrative and regulatory burdens on Health IT and EHR systems will depend on the details. Details that may be more complex and challenging than in any other sector of the American economy. When one considers the size of the industry ($3.3 Trillion, representing close to 20% of GDP), the scope and scale of this challenge makes sense.

Taking a Larger View of the Patient Journey

The EHR and Health IT problems facing healthcare are not confined to clinically-related functionality. They affect every other aspect of the patient’s experiences. In their respective statements, CMS Administrator Verner and Dr. Gawande point out how flaws in EHR and other Health IT systems can compromise patient safety. Often missed in this discussion, however, are other aspects of the patient’s care experience. Specifically, the financial dimension of care.

In an article published by Loyale Healthcare last year titled, “Electronic Medical Record Systems: Powerful for Clinical Engagement, A Liability for Patient Financial Engagement”, Loyale CEO Kevin Fleming focused not on the clinical deficiencies inherent to these disparate, overly complicated systems but to the financial and administrative obstacles they have placed between patients and their care. Mr. Fleming also noted how the massive investments of time, effort and money necessary to deploy and operate these systems often create organizational fatigue that blinds healthcare providers to other investments with the potential to improve the performance of their EHR to provide patients with better access and experiences.

In our view, improved patient access and experiences are relevant at the beginning of a patient’s care journey, when the decision whether or not to seek care is made. Astonishingly for more than half of Americans at that early stage, out-of-pocket costs are the deciding factor. According to research published late last year, 51% of survey respondents said that they had avoided care due to an inability to pay. 78% have been afraid to go to the hospital because of cost. For patients, affordability has become a healthcare crisis.

For many healthcare providers, affordability is synonymous with transparency; more specifically, the ability for patients to know what the cost for their care will be in advance, before treatment has begun. This issue was explored in greater detail in a more recent Loyale article examining another CMS initiative. Titled “Medicare’s Price Transparency Rules Alone Don’t Deliver What Patients Need – A Patient-First Approach Does.

In this article, Mr. Fleming applauds CMS’s intentions. However, like the AHA’s criticism of the new HHS strategy to reduce EHR burdens, he notes that the rules themselves are inadequate for achieving their stated objectives. “CMS rules threaten to distract providers and payers from the larger, more important issue facing healthcare and patients. That issue is patient financial engagement.” To that end, five essential healthcare deliverables were described:

1.    Present upfront cost estimates for the anticipated course of treatment and all associated expenses, including pre-service eligibility so a reliable out-of-pocket estimate is also presented.

2.    Offer multiple payment options to address patient affordability. The Loyale Affordability Workbench, for example, offers provider-configured options that may include discounts for prompt or upfront payment; short-term interest free financing; or longer-term payment plans funded by third party lenders with a reputation for client care.

3.    Interactive self-service options with secure personalized experiences that measure up to the best online experiences consumers have with trusted brands like Amazon, Apple, Zappos and other industry leaders. This is the new standard by which providers will be measured.

4.    Personalized, contextual digital communications that honor each patient’s preferences and behavior. For some providers up until recently, every patient with an unpaid balance became little more than a number – a balance to be collected. In an industry dedicated to health and well-being, no provider can hope to compete without engaging in the financial dimension of care.

5.    End-to-end data analytics, so providers have the information they need to make evidence-based decisions about their patient-pay portfolios and manage for success – as care givers and as business operators.

Many of the same flaws affect both HHS’s new EHR Burden Reduction Strategy and CMS’s Price Transparency rules. Fortunately, the remedies for both are similar. The solution calls for developing a platform approach to healthcare’s operating model. An approach that incorporates multiple system inputs into a single, manageable whole. One that makes sense for provider-users and delights patients at the same time. At Loyale, we are confident our industry will succeed in hitting that mark.

Kevin Fleming is the CEO of Loyale Healthcare

About Loyale

Loyale Patient Financial Manager™ is a comprehensive patient financial engagement technology platform leveraging a suite of configurable solution components including predictive analytics, intelligent workflows, multiple patient financing vehicles, communications, payments, digital front doors and other key capabilities.

Loyale Healthcare is committed to a mission of turning patient responsibility into lasting loyalty for its healthcare provider customers. Based in Lafayette, California, Loyale and its leadership team bring 27 years of expertise delivering leading financial engagement solutions for complex business environments. Loyale currently serves approximately 12,000 healthcare providers across 48 states. Loyale is proud to be an enterprise-level strategic partner with Parallon, including deployment of Loyale’s industry leading technology to all HCA hospitals and Physician Groups.